Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by SouthState Corp

SouthState Corp raised its position in Becton, Dickinson and Company (NYSE:BDX) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,341 shares of the medical instruments supplier’s stock after buying an additional 72 shares during the quarter. SouthState Corp’s holdings in Becton, Dickinson and Company were worth $1,790,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Sapient Capital LLC acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at $1,295,000. Vest Financial LLC raised its stake in Becton, Dickinson and Company by 27.5% during the 4th quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock valued at $25,115,000 after acquiring an additional 22,207 shares during the last quarter. M. Kulyk & Associates LLC lifted its position in Becton, Dickinson and Company by 5.1% during the 3rd quarter. M. Kulyk & Associates LLC now owns 16,640 shares of the medical instruments supplier’s stock worth $4,302,000 after acquiring an additional 809 shares during the period. SG Americas Securities LLC grew its stake in shares of Becton, Dickinson and Company by 69.4% in the 4th quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock valued at $3,685,000 after purchasing an additional 6,190 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Becton, Dickinson and Company by 1.1% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 714,114 shares of the medical instruments supplier’s stock valued at $174,122,000 after purchasing an additional 7,790 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX traded down $5.73 during trading hours on Friday, reaching $234.62. The company had a trading volume of 1,722,348 shares, compared to its average volume of 1,413,846. The company has a market capitalization of $67.78 billion, a price-to-earnings ratio of 55.61, a PEG ratio of 1.93 and a beta of 0.45. Becton, Dickinson and Company has a 12-month low of $229.40 and a 12-month high of $287.32. The firm has a 50 day simple moving average of $238.68 and a 200-day simple moving average of $240.71. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same period last year, the company posted $2.86 EPS. The company’s revenue was up 4.6% on a year-over-year basis. Research analysts expect that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be issued a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. Becton, Dickinson and Company’s payout ratio is 90.05%.

Analyst Upgrades and Downgrades

Separately, Barclays upped their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.